Stifel Financial Corp Has $84,000 Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

Stifel Financial Corp trimmed its position in Fate Therapeutics, Inc. (NASDAQ:FATE) by 41.9% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 24,096 shares of the biopharmaceutical company’s stock after selling 17,391 shares during the period. Stifel Financial Corp’s holdings in Fate Therapeutics were worth $84,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in FATE. Ausdal Financial Partners Inc. bought a new stake in shares of Fate Therapeutics in the second quarter valued at about $33,000. Dark Forest Capital Management LP acquired a new stake in Fate Therapeutics in the 2nd quarter worth about $63,000. DRW Securities LLC bought a new stake in Fate Therapeutics in the 2nd quarter valued at about $71,000. Castleview Partners LLC acquired a new position in shares of Fate Therapeutics during the 3rd quarter worth approximately $73,000. Finally, Arizona State Retirement System bought a new position in shares of Fate Therapeutics during the second quarter worth approximately $84,000. Institutional investors own 97.54% of the company’s stock.

Fate Therapeutics Stock Performance

Shares of FATE opened at $1.62 on Tuesday. Fate Therapeutics, Inc. has a 52-week low of $1.55 and a 52-week high of $8.83. The firm has a market cap of $184.51 million, a price-to-earnings ratio of -0.98 and a beta of 1.95. The business’s fifty day moving average is $2.38 and its 200-day moving average is $3.25.

Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.02. The firm had revenue of $3.07 million for the quarter, compared to analysts’ expectations of $0.88 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. As a group, research analysts forecast that Fate Therapeutics, Inc. will post -1.72 EPS for the current fiscal year.

Analyst Ratings Changes

FATE has been the subject of several recent research reports. Wedbush reiterated a “neutral” rating and issued a $5.00 price target on shares of Fate Therapeutics in a research note on Tuesday, November 12th. Bank of America raised Fate Therapeutics from an “underperform” rating to a “neutral” rating in a report on Monday, November 18th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $6.75.

Insider Activity at Fate Therapeutics

In other news, Director Redmile Group, Llc acquired 397,964 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were bought at an average price of $1.68 per share, with a total value of $668,579.52. Following the acquisition, the director now directly owns 12,884,277 shares in the company, valued at $21,645,585.36. The trade was a 3.19 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 5.00% of the stock is currently owned by insiders.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.